Drug intelligence / Profile preview

ESO157-170

Development stage: Unknown
Modality: Peptides, Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

**ESO157-170** is a synthetic peptide vaccine corresponding to amino acids 157–170 of the NY-ESO-1 cancer-testis antigen. It is designed to induce cellular immune responses against NY-ESO-1-expressing tumors by stimulating both **CD4+ (helper)** and **CD8+ (cytotoxic) T cells**. Mechanistically, ESO157-170 acts as an epitope recognized by HLA-DP4-restricted CD4+ T cells and HLA-A2-/A24-restricted CD8+ T cells, promoting a Th1 biased cytokine response characterized by secretion of IFN-γ, TNF-α, and IL-2. ESO157-170 has been investigated in phase I clinical trials in patients with **epithelial ovarian cancer (EOC)**, formulated with Montanide ISA-51 adjuvant. Induced T cell clones were shown to recognize and destroy NY-ESO-1 expressing tumor cells. The vaccine's immunogenicity results in long-lived functional memory T cells, and it has potential utility in cancer immunotherapy, especially for tumors expressing NY-ESO-1[2][3][4].

Other names: NY-ESO-1 157–170

Targets

HLA-A*24:02/NY-ESO-1(158-166) (Human leukocyte antigen A*24:02 (HLA-A*24:02) presenting NY-ESO-1 (158-166) peptide)pMHC-I (Peptide–MHC class I complex)HLA-DP4/NY-ESO-1(157-170) (Human Leukocyte Antigen DP4 (HLA-DP4) presenting NY-ESO-1 (157-170) peptide complex)

Beyond the preview

Go deeper on ESO157-170.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ESO157-170.

Explore the full profile